Scarica l'app Stockscreener
43.10
4.14%
-1.86
Dopo l'orario di chiusura:
43.28
0.18
+0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$44.96
Aprire:
$44.13
Volume 24 ore:
22.62M
Relative Volume:
1.14
Capitalizzazione di mercato:
$62.46B
Reddito:
$20.62B
Utile/perdita netta:
$3.56B
Rapporto P/E:
18.07
EPS:
2.3847
Flusso di cassa netto:
$3.48B
1 W Prestazione:
-8.20%
1M Prestazione:
-14.59%
6M Prestazione:
-38.39%
1 anno Prestazione:
-59.04%
Intervallo 1D:
$42.78
$44.42
Intervallo di 1 settimana:
$42.78
$48.06
Portata 52W:
$42.20
$105.72
Boston Scientific Corp Stock (BSX) Company Profile
Nome
Boston Scientific Corp
Settore
Industria
Telefono
508-683-4000
Indirizzo
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, MDT, SYK, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-30 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | Downgrade | Erste Group | Buy → Hold |
| 2025-09-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Iniziato | Leerink Partners | Outperform |
| 2025-04-16 | Aggiornamento | Needham | Hold → Buy |
| 2025-01-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Downgrade | Needham | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-06-30 | Iniziato | CL King | Buy |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-20 | Ripresa | Citigroup | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-06 | Iniziato | Wolfe Research | Outperform |
| 2022-05-27 | Aggiornamento | Needham | Hold → Buy |
| 2022-04-13 | Ripresa | Truist | Buy |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-05-26 | Downgrade | Needham | Buy → Hold |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-17 | Iniziato | Truist | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Peer Perform |
| 2020-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Buy |
| 2019-12-30 | Reiterato | Cowen | Outperform |
| 2019-12-19 | Downgrade | Needham | Strong Buy → Buy |
| 2019-09-05 | Ripresa | JP Morgan | Overweight |
| 2019-09-03 | Ripresa | Barclays | Overweight |
| 2019-05-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Iniziato | UBS | Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-10-02 | Reiterato | Morgan Stanley | Overweight |
| 2018-09-07 | Reiterato | Needham | Strong Buy |
| 2018-09-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-07-06 | Reiterato | Needham | Strong Buy |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-04-26 | Reiterato | Needham | Strong Buy |
Mostra tutto
Boston Scientific Corp Borsa (BSX) Ultime notizie
Why Boston Scientific (BSX) Dipped More Than Broader Market Today - Yahoo Finance
Boston Scientific Corp (BSX) Stock Down 4.1% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Alpha Buying: 4 Falling Knives Insiders Are Buying - Benzinga
Boston Scientific stock falls as cyberattack clouds 2026 guidance - ad-hoc-news.de
Boston Scientific at Wells Fargo conference: cyberattack clouds outlook - Investing.com
Update on recent cybersecurity incident - Boston Scientific
Boston Scientific stock falls as cyberattack prompts guidance cut and BTIG lowers price target - ad-hoc-news.de
Boston Scientific Flags Financial Hit From Cyberattack - BankInfoSecurity
Medtronic Is on the Cusp of Becoming a Dividend King. Is the Stock a Buy for Income Investors? - The Motley Fool
Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
BSX Maintains Buy Rating by BTIG -- Price Target Lowered to $56 - GuruFocus
Boston Scientific says cyberattack likely to hurt 2026 sales, profit By Reuters - Investing.com
Boston Scientific Corp (BSX) Stock Down 5.9% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack - theinsurer.com
Boston Scientific Flags Guidance Miss Amid 'Material Impact' From Cybersecurity Incident; Shares Fall - Yahoo! Finance Canada
Boston Scientific misses 2026 guidance after cyberattack - Yahoo Finance
Boston Scientific Says Cyberattack Will Impact 2026 Results — Says It Is ‘Unlikely’ To Meet Net Sales Growth, EPS Guidance Ranges - Yahoo Finance
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack - Benzinga
Boston Scientific stock falls after 2026 guidance cut - AD HOC NEWS
Damages from med-tech cyberattacks adding up - BioWorld News
Boston Scientific left nursing its bottom line after cyberattack - The Register
Boston Scientific Unlikely to Meet Forecasts After Cyber Attack - Bloomberg.com
Novartis and Boston Scientific Slide, Intel Price Hikes | Stock Movers - Yahoo Finance
Boston Scientific Warns On Earnings After Cyberattack - baystreet.ca
Boston Scientific Says Cyberattack Will Hit Q3 and FY2026 Results and Miss Guidance - Minichart
Boston Scientific Shares Slide After Cyberattack Forces 2026 Guidance Cut - AskTraders
Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead? - Yahoo Finance
Boston Scientific unlikely to meet guidance due to cyberattack - Yahoo Finance
TD Cowen reiterates Boston Scientific stock Buy rating after cyber recovery By Investing.com - Investing.com South Africa
Boston Scientific Unlikely to Meet Net Sales Guidance as Cybersecurity Incident Disrupts Operations - marketscreener.com
Boston Scientific CorpIdentifies Cybersecurity Incident Causing Global Operational DisruptionSEC Filing - TradingView
Boston Scientific Won't Meet Guidance Due to Cyberattack - marketscreener.com
Boston Scientific unlikely to meet Q3FY26 and full-year guidance - scanx.trade
Boston Scientific Won’t Meet Guidance Due to Cyberattack - Yahoo Finance
Why is Boston Scientific stock sliding today? - Investing.com
Why is Boston Scientific stock sliding today? By Investing.com - Investing.com UK
Boston Scientific says cyberattack likely to hurt 2026 sales, profit - marketscreener.com
Boston Scientific says cyberattack likely to hurt 2026 sales, profit targets - marketscreener.com
Cyberattack forces Boston Scientific (NYSE: BSX) to rethink its 2026 outlook - Stock Titan
TD Cowen reiterates Boston Scientific stock Buy rating after cyber recovery - Investing.com Canada
Boston Scientific on road to recovery following cyberattack - Yahoo Finance
Boston Scientific stock holds steady as investors weigh latest medical-device growth story - ad-hoc-news.de
Boston Scientific stock gains support from institutional buying and solid Q2 2026 results - AD HOC NEWS
Recall Recap: Boston Scientific Pacemakers, Baby Formula - Law360
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
TD Cowen reiterates Boston Scientific stock rating on shipping restoration - Investing.com
Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk - Benzinga
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
Boston Scientific (NYSE:BSX) Trades Below Its Cash-Flow Value - Kalkine Media
Boston Scientific Corp Azioni (BSX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):